FDA's Martin Makary Defends Drug Approval Decisions Amid Controversy

FDA Commissioner Martin Makary defended the agency's recent drug rejection decisions in a CNBC interview after facing criticism, particularly regarding a melanoma drug from Replimune. He asserted that three independent teams reached the same conclusion about the drug's unsuitability. Makary emphasized that he does not work for Replimune but for the American public and supported the FDA's scientific integrity. This defense comes amid mounting pressure and reports of internal turmoil at the FDA under his leadership.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.